Assessing taxane-associated adverse events using the FDA adverse event reporting system database

Assessing taxane-associated adverse events using the FDA adverse event reporting system database

Abstract. Background:. Taxanes are an essential class of antineoplastic agents used to treat various cancers and are a fundamental cause of hypersensitivity reactions. In addition, other adverse events, such as bone marrow toxicity and peripheral neuropathy, can lead to chemotherapy discontinuation....

Full description

Bibliographic Details
Main Authors:	Dong-Hui Lao, Ye Chen, Jun Fan, Jian-Zhong Zhang, Peng Lyu.
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-06-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001562

Similar Items

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
by: Long Meng, et al.
Published: (2021-02-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023-11-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.
by: Akiho Fukuda, et al.
Published: (2017-01-01)

Effect of statins on blood pressure: Analysis on adverse events released by FDA
by: Tao You, et al.
Published: (2017-05-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022-12-01)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023-12-01)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
by: Kavanagh KT, et al.
Published: (2019-07-01)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023-04-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024-04-01)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024-01-01)

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
by: Toshiyuki Sakaeda, et al.
Published: (2011-01-01)

Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
by: Wei Chen, et al.
Published: (2024-02-01)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
by: Yusuke Kan, et al.
Published: (2021-05-01)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
by: Qiang Guo, et al.
Published: (2022-11-01)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Pan Ma, et al.
Published: (2022-11-01)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020-09-01)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024-01-01)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
by: Wei Wang, et al.
Published: (2023-09-01)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021-07-01)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
by: Yinghong Zhai, et al.
Published: (2021-09-01)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022-11-01)

Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database
by: Aoi Noda, et al.
Published: (2020-07-01)

Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database
by: Kaito Yamashiro, et al.
Published: (2022-10-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2021-04-01)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
by: Yanchao Yin, et al.
Published: (2022-11-01)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
by: Yang Yang, et al.
Published: (2022-01-01)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
by: Yang Yang, et al.
Published: (2022-01-01)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
by: Menglin Guo, et al.
Published: (2022-11-01)

Evaluating adverse events in databases
by: Katie Lovell, et al.
Published: (2023-10-01)

Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database
by: Fei W, et al.
Published: (2023-08-01)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023-01-01)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
by: Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2011-01-01)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
by: Zhi-Xuan Zhou, et al.
Published: (2022-04-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)